Evidence map›Paper›PMID 38539466›Full record

ReviewCancers2024

DDX3X and Stress Granules: Emerging Players in Cancer and Drug Resistance.

Han Zhang, Paula M Mañán-Mejías, Hannah N Miles, Andrea A Putnam, Leonard R MacGillivray, William A Ricke

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. The Role of Long Noncoding RNAs in Modulation of Stress Granules in Cancer.Journal of cellular and molecular medicine · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. [Indole-3-acetic acid alleviatesNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Han ZhangDivision of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0000-0002-8032-857X
Paula M Mañán-MejíasDivision of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA.
Hannah N MilesDivision of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0000-0002-0952-552X
Andrea A PutnamDepartment of Biomolecular Chemistry, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA.
Leonard R MacGillivrayDepartment of Chemistry, University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0003-0875-677X
William A RickeDivision of Pharmaceutical Sciences, School of Pharmacy, University of Wisconsin-Madison, Madison, WI 53705, USA.
University of Wisconsin–Madison · USUniversity of Iowa · US

Funding

Role of Beta-Catenin in Urinary DysfunctionU54DK104310 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI RICKE, WILLIAM A · 2014 to 2023
$12.8M
University of Wisconsin Prostate SPOREP50CA269011 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI DAVID F. JARRARD, DOUGLAS G. MCNEEL · 2023 to 2026
$10.6M
Elucidating hallmarks of aging in the development of lower urinary tract dysfunction (LUTD)R01DK131175 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI RICKE, WILLIAM A · 2021 to 2024
$2.3M
Estrogen pathways in the development of prostatic fibrosis and lower urinary tract dysfunctionR01DK127081 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI RICKE, WILLIAM A · 2021 to 2024
$2.0M
NCI NIH HHS CA269011NCI NIH HHS P50 CA269011NIDDK NIH HHS DK127081NIDDK NIH HHS DK131175NIDDK NIH HHS R01 DK127081NIDDK NIH HHS R01 DK131175NIDDK NIH HHS U54 DK104310NIDDK NIH HHS U54DK104310
6 · The paper itself

Abstract

The DEAD (Asp-Glu-Ala-Asp)-box helicase 3 X-linked (DDX3X) protein participates in many aspects of mRNA metabolism and stress granule (SG) formation. DDX3X has also been associated with signal transduction and cell cycle regulation that are important in maintaining cellular homeostasis. Malfunctions of DDX3X have been implicated in multiple cancers, including brain cancer, leukemia, prostate cancer, and head and neck cancer. Recently, literature has reported SG-associated cancer drug resistance, which correlates with a negative disease prognosis. Based on the connections between DDX3X, SG formation, and cancer pathology, targeting DDX3X may be a promising direction for cancer therapeutics development. In this review, we describe the biological functions of DDX3X in terms of mRNA metabolism, signal transduction, and cell cycle regulation. Furthermore, we summarize the contributions of DDX3X in SG formation and cellular stress adaptation. Finally, we discuss the relationships of DDX3X, SG, and cancer drug resistance, and discuss the current research progress of several DDX3X inhibitors for cancer treatment.

Indexed as

castration resistanceDDX3Xdouble-negative prostate cancerdrug resistancenovel therapystress granuletranslational repression

Identifiers

PMID38539466
PMCPMC10968774
OpenAlexW4392697113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.